2024-12-06 08:00
Biovica, active in blood-based cancer monitoring, today announces that the company has obtained an out-of-state permit allowing Biovica to offer testing to patients in New York State. Together with previous permits, Biovica is now allowed to offer DiviTum®...
2024-12-02 08:00
Biovica, active in blood-based cancer monitoring, today announces that the company has entered into a commercial agreement (client bill) with one of the largest health insurance companies in the US, with revenues exceeding 100 billion USD. The company...
2024-11-26 08:00
Biovica, active in cancer monitoring, announces that seven abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest breast cancer meeting, San Antonio Breast Cancer Symposium (SABCS) on December 10-13...
2024-10-22 08:00
Biovica, active in blood-based cancer monitoring, has signed a Master Service Agreement (MSA) for TKa testing with a UK-based pharma biotech company. Under this agreement, Biovica will deliver TKa testing services using its DiviTum® TKa assay and...
2024-10-03 08:00
Biovica International AB ("Biovica" or the "Company") announces today the outcome of the exercise of warrants of series TO 3 B issued in connection with the Company's rights issue of units during October 2023. In total, 7,441,387...
2024-09-24 13:30
Monday, September 30, 2024, is the last day for subscription in Biovica's ongoing warrant program, TO3B. Note that some banks and asset managers may have an earlier deadline date for subscription than 30 September 2024. Shareholders should check...
2024-09-23 08:00
Biovica, active in blood-based cancer monitoring, has signed a work order with a value of 2.2 MSEK. This is the company’s largest single work order to date for TKa testing services within its Pharma Services business. The work order is signed with...
2024-09-17 11:00
The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 17 September 2024 and the following resolutions were passed by the meeting. ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEETThe...
2024-09-17 08:30
Biovica, active in blood-based cancer monitoring, has signed a Master Service Agreement (MSA) with a US-based biotech company focusing on next generation CDK inhibitors. Under the agreement, Biovica will provide TKa testing services utilizing Biovica’s...
2024-09-12 10:25
Correction due to missing MAR-legend Significantly increased sales in the USA and much improved cash flow Significant events during the first quarter Significant events after the end of the period Webcast:When: 12 September 2024, 3 PM to 4 PM CETWhere...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects